Last reviewed · How we verify
Aerosolized Tobramycin or Vancomycin
Aerosolized aminoglycoside or glycopeptide antibiotics are inhaled directly into the lungs to achieve high local concentrations that kill susceptible bacteria in respiratory infections.
Aerosolized aminoglycoside or glycopeptide antibiotics are inhaled directly into the lungs to achieve high local concentrations that kill susceptible bacteria in respiratory infections. Used for Chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis patients, Chronic respiratory infections in non-cystic fibrosis bronchiectasis.
At a glance
| Generic name | Aerosolized Tobramycin or Vancomycin |
|---|---|
| Also known as | Tobi, Tobrex; Vancocin |
| Sponsor | Wright State University |
| Drug class | Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin) |
| Target | Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tobramycin and vancomycin are broad-spectrum antibiotics that inhibit bacterial protein synthesis (tobramycin) or cell wall synthesis (vancomycin). When aerosolized, they bypass systemic absorption and deliver high drug concentrations directly to infected lung tissue, particularly useful for chronic respiratory infections in cystic fibrosis and other conditions where systemic dosing may be limited by toxicity or poor lung penetration.
Approved indications
- Chronic Pseudomonas aeruginosa respiratory infection in cystic fibrosis patients
- Chronic respiratory infections in non-cystic fibrosis bronchiectasis
Common side effects
- Bronchospasm
- Cough
- Wheezing
- Voice hoarseness
- Tinnitus (tobramycin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aerosolized Tobramycin or Vancomycin CI brief — competitive landscape report
- Aerosolized Tobramycin or Vancomycin updates RSS · CI watch RSS
- Wright State University portfolio CI